ArticleJournal of maxillofacial and oral surgery2025
Expression of Salivary and Serum IGF-1 and IGFBP-3 in Individuals With Diabetes and Oral Cancer.
Article in Journal of maxillofacial and oral surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood and Saliva Composition in Cancer: Similarities or Differences?Current issues in molecular biology · 2026Review
- Comparison of salivary caspase-3 biomarker in peri-implantitis among type 2 diabetic patients.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate the expression of salivary and serum Insulin-like growth factor-1 (IGF-1) and Insulin-like growth factor binding protein-3 (IGFBP-3) in individuals with and without diabetes and oral cancer. Methods: The cross-sectional study included 4 groups ( Results: Serum IGF-1 levels [Median (Inter-quartile range)] were highest among the control group [255 (135) ng/ml], followed by only T2D group [210 (147) ng/ml], oral cancer with T2D group [149 (45) ng/ml] and finally the oral cancer group [143 (81) ng/ml, p for trend = 0.004]. Salivary IGF-1 values were significantly higher in both the groups with T2D [T2D:0.42 (0.20) ng/ml; oral cancer with T2D: 0.40 (0.21) ng/ml] when compared to those with only oral cancer [0.27 (0.06) ng/ml] and controls: 0.17 (0.17) ng/ml], p for trend = 0.007]. Serum IGFBP-3 was significantly higher in both the oral cancer groups [without T2D: 13.1(10.4) ng/ml; with T2D: 14.9 (8.5) ng/ml] compared to only T2D [0.27 (0.06) ng/ml] and controls [8.7 (3.5) ng/ml, Conclusion: IGF-1 and IGFBP-3 are not reliable biomarkers for oral cancer screening or risk prediction. Further research is needed to confirm if they can be used as prognostic tools during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.